Global poliovirus risk management and modeling

February 16, 2021

Launched in 1988, the Global Polio Eradication Initiative (GPEI) stands out as one of the largest, internationally coordinated global public health major projects conducted to date, with cumulative spending of over $16.5 billion for 1988-2018, according to the World Health Organization (WHO). More than 30 years later, stubborn outbreaks of wild poliovirus still occur in Afghanistan and Pakistan, where cases have been increasing since 2018. The global eradication of polio continues to be an elusive goal.

A special issue of the journal Risk Analysis, titled "Global Poliovirus Risk Management and Modeling," looks at the current status of polio eradication efforts and evaluates the GPEI strategies from its 2019-2023 strategic plan. The February 2021 issue includes 13 research papers published within the last year in Risk Analysis along with an introductory Perspective written by Dr. Kimberly Thompson, an expert on modeling polio and founder of Kid Risk, Inc., a non-profit organization focused on pediatric risk analysis. This is the third special issue on poliovirus published by Risk Analysis, with prior issues in 2006 and 2013.

"With each special issue, we have expected a successful polio endgame within a few years of publication," says Dr. Thompson, who led several of the studies. "But challenges remain." The first paper in the special issue offers a reflection on prior modeling that delves into the differences between model projections for 2013-2020 and what actually occurred. Dr. Thompson highlights that "in contrast to prior modeling that focused on identifying the best strategies, the modeling in the current special issue focuses on actual practice and GPEI plans, and it assumes realistic, non-optimal GPEI and country performance based on recent experience." The second paper in the special issue shows the estimated cases for 2019-2023 with these assumptions and demonstrates the GPEI was off track even before the COVID-19 pandemic disrupted polio immunization activities.

There has been some positive news in the last few years. The GPEI certified the global eradication of type 2 wild poliovirus (WPV2) in 2015 and type 3 (WPV3) in 2019. In August 2020, the World Health Organization's (WHO's) African Region certified the regional elimination of all wild polioviruses in Africa. But type 1 (WPV1), the most transmissible and virulent type of poliovirus, continues to transmit in parts of Pakistan and Afghanistan.

With respect to the situation for vaccine-derived poliovirus cases of type 2, the special issue includes papers that show the increasing risks of globally needing to restart the use of OPV in preventive immunization and the potential impacts of using new OPV strains for type 2 outbreak response. In addition, the last paper of the special issue provides an updated health and economic analysis of the GPEI, which shows that it still promises substantial incremental net benefits compared to the counterfactual of no GPEI. However, delays in achieving polio eradication and the adoption of expensive immunization strategies have taken a toll. In contrast to a 2011 analysis that suggested incremental net benefits on the order of $40-50 billion in 2008 US dollars, which would be equivalent to $48-59 billion in 2019 US dollars, the updated economic analysis suggests incremental net benefits of the GPEI of around $28 billion 2019 US dollars if the GPEI partners can finish the job.

The COVID-19 pandemic has further complicated projections as population mixing changed and polio vaccinations were delayed. "Future analyses will need to explore the implications of the COVID-19 pandemic on polio eradication and other disease control and elimination efforts," adds Dr. Thompson. For those who may recall the media blitz last summer related to a suggestion to use OPV to respond to COVID-19 while waiting for COVID-19 specific vaccines, the special issue includes a study that characterizes the substantial risks and costs of reintroducing OPV in the US.

In alignment with the GPEI's strategic plan for 2019-2023, the studies included in the Risk Analysis issue focus on the status of polio eradication efforts at the beginning of this plan and the expected trajectory of the disease prior to the onset of the COVID-19 pandemic. "Future analyses will need to explore the implications of the COVID-19 pandemic on polio eradication and other disease control and elimination efforts," adds Dr. Thompson.

Research topics in the special issue include:Integrated risk, economic, and dynamic transmission modeling offers a tool to support national and global health leaders as they evaluate the increasingly complicated choices in the polio endgame. "While we optimistically believe that polio eradication remains possible and that it should be done, we also believe that the GPEI is not on track to achieve it," says Dr. Thompson. "Modeling can identify strategies that could still be implemented to finish the job more cost-effectively."
About SRA

The Society for Risk Analysis is a multidisciplinary, interdisciplinary, scholarly, international society that provides an open forum for all those interested in risk analysis. SRA was established in 1980 and has published Risk Analysis: An International Journal, the leading scholarly journal in the field, continuously since 1981. For more information, visit

Society for Risk Analysis

Related Polio Eradication Articles from Brightsurf:

The Lancet: New polio vaccine against strain that threatens eradication is safe and generates immune response in adults, young children, and infants
Scientists have developed the first poliovirus vaccine against a mutated form of the disease that is causing disease outbreaks across Africa and Asia.

How the polio vaccine virus occasionally becomes dangerous
The polio vaccines, developed by Jonas Salk and Albert Sabin in the mid-1950s, heralded the elimination of polio from the U.S., saving countless children from sudden paralysis and death.

Protective antibodies identified for rare, polio-like disease in children
Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection.

In victory over polio, hope for the battle against COVID-19
Medicine's great triumph over polio holds out hope we can do the same for COVID-19, two researchers say.

'Designer virus' is first new polio vaccine in 50 years
UC San Francisco virologist Raul Andino, PhD and Andrew Macadam, PhD, of the UK's National Institute for Biological Standards and Control (NIBSC) report promising Phase 1 clinical results for the first new oral polio vaccine in 50 years, which they have designed to be incapable of evolving the ability to cause disease in humans.

Global eradication of 'fly of death' not ethically justified, researchers conclude
Oregon State University researchers argue that human-caused extinction of the tsetse fly would be unethical, but elimination campaigns targeting isolated populations of the fly are ethically defensible.

Polio-like illness mostly of children is focus of 3 JAMA Pediatrics articles
Acute flaccid myelitis (AFM) is a poorly understood polio-like illness mostly of children characterized by weakness of muscles and limbs and the presence of a spinal cord lesion.

Freeze-dried polio vaccine could spell end of disease
Injectable vaccine, freeze-dried into a powder, kept at room temperature for four weeks and then rehydrated, offered full protection against the polio virus when tested in mice.

Possible treatment for rare polio-like illness shows no benefit
Researchers have been searching for possible treatments for the polio-like illness causing paralysis in children, called acute flaccid myelitis.

Zika circulates among wild animals in the Americas, making eradication nearly impossible
A collaborative group of researchers from The University of Texas Medical Branch at Galveston and the Faculty of Medicine of Sao Jose do Rio in Brazil is the first to report that wild monkeys in the Americas are transmitting the Zika virus to humans via mosquitoes, making complete eradication of the virus in the Americas very unlikely.

Read More: Polio Eradication News and Polio Eradication Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to